KemPharm Inc. (KMPH)

1.67 +0.01 (+0.602%)

IEX Real-Time Price

April 23, 2019 EST.

NASDAQ Global Market : Healthcare

Prev Close 1.66

Price Open 1.65

Volume: 276,110

Avg Volume: 267,130

Market Cap: 44.55M

P/E Ratio -0.53

52 Wk Range 1.57-7.15



KMPH Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
15.76M
424,005
0.96
2.69%

2018-09-28
15.76M
1.15M
13.64
7.33%

2018-09-14
15.76M
1.34M
25.13
8.48%

2018-08-31
15.76M
1.35M
19.07
8.58%




KMPH Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-08
Q3 2018
AMC
-0.74 (3)
-0.94
-0.20

2018-08-09
Q2 2018
AMC
-0.98 (3)
-0.91
0.07

2018-05-10
Q1 2018
AMC
-0.70 (2)
-1.11
-0.41

2018-05-09
Q1 2018
N/A
-0.67 (2)
0.00
0.00

News

FDA OKs first non-drug treatment for ADHD (2019-04-20 18:08 SeekingAlpha)

The FDA has approved privately held NeuroSigma 's Monarch eTNS System for the first-line treatment of patients ages 7 - 12 years old with attention deficit hyperactivity disorder (ADHD), the first non-drug therapy for the condition available in the U.S. More news on: KemPharm, Inc., Sup…

 


Statistics

Shares Outstanding: 26.68M

Top 15 Institution Percent: 38.20

Price To Sales: N/A

Price To Book: 162.74

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -146.74

Return On Equity: 92.85

Profit Margin: N/A

Price History

Beta: 1.70

50-day Moving Avg: 1.98

200-day Moving Avg: 3.12

YTD Change: -15.66

5-day Change: -0.60

1-month Change: -11.17

3-month Change: -37.69

6-month Change: -32.93

1-year Change: -70.70

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: KemPharm Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.kempharm.com

KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs.